Clinical Trial Update: The COVID-RASi Trial (COVID-19) [Phase 3]

View source ↗

Summary

Phase 3 COVID-19 trial evaluating RAS inhibitors has completed; no results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: COVID-19, Cardiovascular Diseases | Phase 3 | Status: COMPLETED